| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We made BCR-ABL positive iPS cells and analyze the phenotype, cell proliferation and efficacy of ABL inhibitors in iPS cells. Because the association between AMPK and Hippo pathway has been reported, we investigated the effect of AMPK on Ph-positive leukemia. Pioglitazone induced cell growth inhibition in a concentration-dependent manner in Ph-positive leukemia cells and enhanced AMPK phosphorylation. Co-treatment with pioglitazone and ABL inhibitor decreased the expression of BCR-ABL in CML patient. Pioglitazone may possess promising clinical relevance as a candidate therapeutic agent for Ph-positive leukemia in the future.
|
